Why is "Aldesleukin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-09 13:25:20
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Aldesleukin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-09 and was most recently seen on 2026-04-09.
Wikipedia Overview
Interleukin-2 (IL-2) is an interleukin, which is a type of cytokine signaling molecule forming part of the immune system. It regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes. The major sources of IL-2 are activated CD4+ T cells and activated CD8+ T cells. Put shortly, the function of IL-2 is to stimulate the growth of helper, cytotoxic and regulatory T cells.
Related Topics
Trending Topic Today
Search Interest Perspective
-
Imneskibart Plus Aldesleukin Yields Antitumor Activity in Melanoma and NSCLC - Targeted Oncology
-
Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts - CancerNetwork
-
CPI-refractory cutaneous melanoma: Imneskibart plus low-dose IL-2 shows early disease control - Vera Health
-
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting - BioSpace
-
Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma - Clinical Trials Arena
-
Targeting the immune system could prevent future heart attacks, clinical trial suggests - University of Cambridge
-
Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial - ALS News Today
-
After a heart attack, this treatment could prevent the worst : and researchers are optimistic - Futura, le média qui explore le monde
-
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials - Nature
-
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease - NEJM Evidence
-
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial - The Lancet
-
Clinigen’s Aldesleukin Earns FDA’s Orphan Drug Designation as ALS Treatment - ALS News Today
-
Novartis to divest Proleukin’s US rights to Clinigen for $210m - Pharmaceutical Technology
-
IL-2 based cancer immunotherapies: an evolving paradigm - Frontiers
-
Rutgers Assesses E7 TCR T-Cell Therapy in Phase 1/2 Trial for HPV-Associated Tumors - CGTLive®
-
AU-007 Appears Safe and Effective for Solid Tumors, Phase 2 Findings Show - Targeted Oncology
-
Restoring IL-2 to its cancer immunotherapy glory - Nature
-
Anti-inflammatory drug could reduce future heart attack risk - University of Cambridge
-
Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting - BioSpace
-
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism - Nature
-
Aulos Bioscience doses first patient in avelumab lung cancer trial - Clinical Trials Arena
-
Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received - OncLive
-
Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers - Rutgers University
-
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy - Nature
-
Optimal nurse:patient ratio for patients on IL-2 - Oncology Nurse Advisor
-
Prosetin Gets Orphan Drug Status for ALS - NeurologyLive
-
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million - GlobeNewswire
-
The application of cytokines within cancer immunotherapy - News-Medical
-
ReAlta secures FDA orphan drug and fast track designations for GvHD therapy - Pharmaceutical Technology
-
Synthekine dosed first patient in Phase 1 trial of its IL-2 treatment STK-012 in solid tumors - PPF Group
-
FDA grants clearance to Prilenia and Ferrer’s Phase III ALS therapy trial - Clinical Trials Arena
-
AZD-6750 enhances CD8+ T-cell activity - BioWorld News
-
Clinigen buys Novartis’ cancer drug Proleukin, eyes new combos - Fierce Biotech
-
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma - The New England Journal of Medicine
-
Tiglutik, Liquid Form of Riluzole, Now Available in US for ALS Treatment - ALS News Today
-
Patient drug trial to improve recovery from heart attack - Cambridge University Hospitals
-
Elysium Health’s EH301 Designated Orphan Drug by FDA for Treatment of ALS - ALS News Today
-
New Dynamic Neck Brace May Improve Head, Neck Range of Motion for ALS Patients, Study Says - ALS News Today
-
New research finds Motor Neuron Disease drug safe and effective at low doses - King's College London
-
Hope for new heart attack treatment targeting dangerous immune response - British Heart Foundation
-
Synthorx Gears Up for IPO - 24/7 Wall St.
-
Team praised for “game-changing” heart trial - Cambridge University Hospitals
-
Hanmi partners with MSD to trial immune anticancer drug HM16390 with Keytruda - CHOSUNBIZ - Chosunbiz
-
Global spotlight on Cambridge heart trial - NIHR Cambridge Biomedical Research Centre
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.